Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8024487 | 0.89 | BACE1 (0.62) | BACE1HTTTRPV1ALDH1A1HPGD | |
| SCHEMBL1587488 | 0.86 | ACHE (0.48) | BACE1TRPV1ACHE | |
| SCHEMBL1587489 | 0.86 | ACHE (0.48) | BACE1TRPV1ACHE | |
| SCHEMBL12702693 | 0.85 | ACHE (0.49) | BACE1TRPV1ALDH1A1ACHE | |
| SCHEMBL8019433 | 0.84 | BACE1 (0.57) | BACE1HTTTRPV1 | |
| SCHEMBL8009478 | 0.82 | BACE1 (0.81) | BACE1HTTALDH1A1HPGDPTPN1 | |
| SCHEMBL1586722 | 0.82 | BACE1 (0.81) | BACE1HTTALDH1A1HPGDPTPN1 | |
| SCHEMBL1587245 | 0.82 | BACE1 (0.81) | BACE1HTTALDH1A1HPGDPTPN1 | |
| SCHEMBL30392401 | 0.82 | BACE1 (0.81) | BACE1HTTALDH1A1HPGDPTPN1 | |
| SCHEMBL1586724 | 0.82 | BACE1 (0.81) | BACE1HTTALDH1A1HPGDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| WO-2009098287-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA S.A. (ES) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092591-A1 | PHENYL-PRENYL DERIVATIVES, OF MARINE AND SYNTHETIC ORIGIN, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PSEN1, PARK7, APP | BACE1 8/4885HTT 50/4885TRPV1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.